Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Operating expenses:        
Research and development $ 1,467,736 $ 824,094 $ 1,938,712 $ 1,368,396
General and administrative 2,674,920 1,072,169 4,078,385 2,231,458
Total operating expenses 4,142,656 1,896,263 6,017,097 3,599,854
Operating loss (4,142,656) (1,896,263) (6,017,097) (3,599,854)
Change in fair value of common stock warrants   (152,447)   (152,447)
Warrant financing expense   (192,817)   (192,817)
Other income 79 38 138 75
Loss before income taxes (4,142,577) (2,241,489) (6,016,959) (3,945,043)
Net loss (4,142,577) (2,241,489) (6,016,959) (3,945,043)
Deemed dividends attributable to preferred stock (4,782,100) (2,568,132) (4,782,100) (2,568,132)
Net loss applicable to common stockholders $ (8,924,677) $ (4,809,621) $ (10,799,059) $ (6,513,175)
Loss per common share - basic and diluted (in dollars per share) $ (2.90) $ (7.72) $ (3.77) $ (13.85)
Weighted average shares outstanding, basic and diluted (in shares) 3,073,803 623,004 2,864,033 470,139